Bemfivastatin (hemicalcium)

Bemfivastatin (PPD 10558) hemicalcium is an orally active HMG-CoA Reductase (HMGCR) inhibitor. Bemfivastatin hemicalcium enhances the activity of liver extraction and reduces blood lipid levels. Bemfivastatin hemicalcium can be used for research of metabolic disease, such as hypercholesterolemia[1][2].

Product Specifications

CAS Number

[805241-64-9]

Product Name Alternative

PPD 10558 (hemicalcium)

UNSPSC

12352005

Target

HMG-CoA Reductase (HMGCR)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/bemfivastatin-hemicalcium.html

Purity

98.00

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

[O-]C(C[C@H](O)C[C@H](O)CCN1C(C2=CC=C(F)C=C2)=C(C3=CC=CC=C3)C(C(NC4=CC=C(CO)C=C4)=O)=C1C(C)C)=O.[Ca+2].[1/2]

Molecular Formula

C34H36FN2O6.1/2Ca

Molecular Weight

607.74

References & Citations

[1]Faqi AS, et al. Developmental toxicity of the HMG-CoA reductase inhibitor (PPD10558) in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol. 2012 Feb;95 (1) :23-37.|[2]Wierzbicki A, et al. Drugs in development for the management of dyslipidaemia[J]. Future Prescriber, 2012, 13 (2) : 12-15.